Molecular Formula | C17H16BrF4NO2 |
Molar Mass | 422.21 |
Density | 1.488±0.06 g/cm3(Predicted) |
Boling Point | 478.5±40.0 °C(Predicted) |
Solubility | DMSO : 250 mg/mL (592.12 mM);H2O : < 0.1 mg/mL (insoluble) |
pKa | 14.74±0.10(Predicted) |
Storage Condition | -20°C |
In vivo study | USP25/28 inhibitor AZ1 (AZ1; 40 mg/kg; gavage; daily; for 7 days) protects from dextran sulfate sodium (DSS)-induced weight loss and diarrhea and impaired colon shortening. USP25/28 inhibitor AZ1 (20 mg/kg/day; gavage; 6 times a week in the 1, 3, 6 weeks) treatment significantly reduces tumor numbers in colons. Expression of Wnt-related genes and levels of pSTAT3 are decreased and levels of SOCS3 are increased in tumors. AZ1 gavage does not alleviate DSS-induced colitis in Usp25 -/- mice or the spontaneous colitis of Il10 -/- mice. USP25/28 inhibitor AZ1 (20 mg/kg/day; gavage; every 3 days from 13-20 weeks) significantly inhibits tumorigenesis in the colon and prolonged the survival of AOM/Vil-Cre;Trp53 fl/fl (VP) mice. AZ1 treatment has minimal effect on tumorigenesis in the USP25-deficient background. Animal Model: 12-week old male Usp25 +/+ and Usp25 -/- mice Dosage: 40 mg/kg Administration: Gavage; daily; for 7 days Result: Protected from dextran sulfate sodium (DSS)-induced weight loss and diarrhea and impaired colon shortening and potentiated the expression of proinflammatory cytokines and antibacterial peptides in colons of Usp25 -/- mice compared to control counterparts. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.368 ml | 11.842 ml | 23.685 ml |
5 mM | 0.474 ml | 2.368 ml | 4.737 ml |
10 mM | 0.237 ml | 1.184 ml | 2.368 ml |
5 mM | 0.047 ml | 0.237 ml | 0.474 ml |